Positron Emission Tomography (PET) and PET/CT



Positron Emission



¹⁸F

- start with neutron-deficient isotope
- decays to stable form by converting a proton to a neutron and ejects a 'positron' to conserve electric charge
- positron annihilates with an electron, releasing two anti-colinear high-energy <u>annihilation photons</u>



Energy Spectrum of Emitted Positrons



Max β^{+} Isotope (Mev) ¹¹C 0.97 ¹³N 1.20 ¹⁵O 1.74 ¹⁸F 0.64 ⁶⁴Cu 0.66 ⁶⁸Ga 1.90 ⁸²Rb 3.35 ⁹⁴Tc 2.47

Medically Useful Positron Emitting Isotopes

ls	otope	Half life (min)	Most probable energy (keV)	FWHM of positron range* in water (mm)
	${}^{18}_{9}F$	109.7	203	0.102
8 3	${}^{32}_{7}Rb$	1.3	1384	0.169
-	${}^{11}_{6}C$	20.3	326	0.111
	$^{13}_{7}N$	10.0	432	0.142
	¹⁵ ₈ O	2.0	696	0.149

90% of all clinical studies

* very long tails

Scintillation Detectors



Scintillators tried in PET

Material	Density	Emission	Decay	Refractive	Relative	Hygro-
	(g/cm3)	Maximum	constant	index	light	scopic
					output	
Na(Tl)	3.67	415 nm	0.23 ms	1.83	100	yes
CsI(Tl)	4.51	550 nm	0.6/3.40 ms	1.79	45	no
CaF2	3.18	435 nm	0.84 ms	1.47	50	no
BaF2	4.88	315/220 nm	0.63 ms	1.50	16	no
			0.80 ns	1.54	5	
YAP(Ce)	5.55	350 nm	27.00 ns	1.94	35-40	no
GSO(Ce)	6.71	440 nm	30-60.00 ns	1.85	20-25	no
LSO(Ce)	7.40	420 nm	40.00 ns	1.82	75	no
BGO	7.13	480 nm	0.30 ms	2.15	15-20	no
CdWO4	7.90	470/540 nm	20/5.00 ms	2.30	25-30	no

Used in commercial scanners

PET Detector Block

- PET scanners are assembled in block modules
- Each block uses a limited number of PMTs to encode an array of scintillation crystals



signal out to

processing

PET Scanner Detector Ring



Block formation for a current PET scanner



Key feature of PET: Line of response collimation by coincidence timing



• In SPECT this is achieved though use of a collimator

• In CT the known geometry from source to detector is used

Time of Flight (TOF) PET/CT



PET Imaging Equation

With enough coincident events for each *line of response*, we can approximate measures as *line-integral* data of the radioisotope concentration A(x,y)



$$\phi(l,\theta) = \int_{-\infty}^{\infty} A(x(s), y(s)) ds$$

The integral is along a line

$$L(l,\theta) = \left\{ (x,y) | x \cos \theta + y \sin \theta = l \right\}$$

Solving the PET Imaging Equation

We have a simple 2D x-ray (Radon) transform, i.e. line integral, that can be exactly solved by filtered backprojection (FBP)

PET Imaging equation
$$\phi'(l,\theta) = \int_{-\infty}^{\infty} A(x(s), y(s)) ds$$

$$A(x,y) = \int_0^{\pi} \left[\int_{-\infty}^{\infty} \left| \rho \right| \Phi(\rho,\theta) e^{j2\pi\rho l} \, d\rho \right] d\theta$$

where $\Phi(\rho, \theta) = \mathscr{F}_{1D} \left\{ \phi'(l, \theta) \right\}$

Typical use case: Glucose metabolism imaging



CT image showing suspicious nodule

PET image confirming cancer



Combined PET/CT imaging combines functional and anatomical imaging (like SPECT/CT)



PET Image of Function

Function+Anatomy

CT Image of Anatomy

PET/CT scanner arrangement



All 3 (couch, CT and PET) must be in accurate alignment

Commercial/Clinical PET/CT Scanner



Confounding effects



Corrections have to be applied for these effects

Attenuation in PET Imaging

2 anti-colinear photons along the line of response (LOR)



Attenuation in PET Imaging

Total number of annihilation photons arriving in coincidence N_c is N_o (activity at s_o) reduced by the product of the attenuation factors

$$N_{C} = N_{0} \exp\left\{-\int_{S_{0}}^{R} \mu(x(s'), y(s'); E) ds'\right\} \exp\left\{-\int_{-R}^{S_{0}} \mu(x(s'), y(s'); E) ds'\right\}$$
$$= N_{0} \exp\left\{-\int_{-R}^{R} \mu(x(s'), y(s'); E) ds'\right\} \text{ key step is combining integrals}$$

We can now allow for a distributed source of positrons along LOR $\phi(l,\theta) = K \int_{-R}^{R} A(x(s), y(s)) \exp\left\{-\int_{-R}^{R} \mu(x(s'), y(s'); E) ds'\right\} ds$ not dependent on *s* so can take out of integral

even better, we now have attenuation as a simple multiplication

$$\phi(l,\theta) = K \int_{-R}^{R} A(x(s), y(s)) ds \cdot \exp\left\{-\int_{-R}^{R} \mu(x(s), y(s); E) ds\right\}$$

Comparison of Imaging Equations



x-ray transform integral along line $L(l,\theta) = \{(x,y) | x \cos \theta + y \sin \theta = l\}$ With rotated coordinates (*l*,*s*) $x(s) = l \cos \theta - s \sin \theta$ $y(s) = l \sin \theta + s \cos \theta$

$$\mathsf{CT} \qquad \phi(l,\theta) = \int_{0}^{E_{\max}} S_0(E) E \exp\left\{-\int_{-R}^{R} \mu(x(s'), y(s'); E) ds'\right\} dE$$

$$\mathsf{SPECT} \quad \phi(l,\theta) = \int_{-\infty}^{R} \frac{A(x(s), y(s))}{4\pi(s-R)^2} \exp\left\{-\int_{s}^{R} \mu(x(s'), y(s'); E) ds'\right\} ds$$

$$\mathsf{PET} \qquad \phi(l,\theta) = K \int_{-R}^{R} A(x(s), y(s)) ds \cdot \exp\left\{-\int_{-R}^{R} \mu(x(s), y(s); E) ds\right\}$$

Attenuation Correction in PET Imaging

We now have attenuation as a simple multiplication

$$\phi(l,\theta) = K \int_{-R}^{R} A(x(s), y(s)) ds \cdot \exp\left\{-\int_{-R}^{R} \mu(x(s), y(s); E) ds\right\}$$

So is we can somehow measure attenuation along the LOR, i.e.

$$a(l,\theta) = \exp\left\{-\int_{-R}^{R} \mu(x(s), y(s); E = 511 \text{keV}) ds\right\}$$

Then we can write

$$\phi'(l,\theta) = \frac{\phi(l,\theta)}{Ka(l,\theta)} = \int_{-\infty}^{\infty} A(x(s), y(s)) ds$$

Which we know how to solve for A(x,y)

Recall that A(x,y) is the radiotracer (positron emitter) concentration that we want to know

How to measure attenuation?

- PET transmission source (68Ge/68Ga): Coincident annihilation photons (mono-energetic @ 511 keV), 265 day half life
- X-ray CT scan: X-rays with a distribution of energies from ~30 to 130 keV (effective energy of ~70 keV)



PET attenuation imaging



- $\mu(x,y)$ values are measured at desired energy of 511 keV
- Near-side detectors, however, suffer from deadtime due to high countrates
- Also subject to bias from emission photons from patient

X-ray CT attenuation imaging



- $\mu(x,y,E)$ is measured as a weighted average from ~30-130 keV, so we need to convert to t $\mu(x,y,E=511 \text{keV})$, potentially introducing bias
- Photon flux is <u>very</u> high, so very low noise and faster than PET transmission imaging

Comparison of attenuation imaging methods



PET TX: 3min, E = 511 keV unbiased estimate, high noise X-ray CT TX: 20 s, E = 30-120 keV biased estimate, low noise

Due to diagnostic superiority of PET/CT, all PET scanners are really PET/CT scanners so we can use CT for attenuation correction

CT-based Attenuation Correction





CT-based Attenuation Correction

- We use the fact that the mass-attenuation coefficient (μ/ρ) is similar for all non-bone materials since Compton scatter dominates for these materials
- Bone has a higher photoelectric cross-section due to calcium
- Can use two different scaling factors: one for bone and one for everything else



CT-based Attenuation Correction

- Bi-linear scaling methods apply different scale factors for bone and non-bone materials
- Should be calibrated for every kVp and/or contrast agent



Data Flow and Processing

CT images are also used for calibration (attenuation correction) of the PET data



- Note that images are not really fused, but are displayed as fused or sideby-side with linked cursors
- Note also that the CT is used for attenuation correction, thus a significant potential for error if there is a mis-alignment or inaccurate scaling

Material artifact: Metal Clip



Artifact

Courtesy O Mawlawi MDACC

Positional artifact: Patient and/or bed shifting

Large change in attenuation at lung boundaries, so very susceptible to errors



PET image without attenuation correction

PET image with CT-based attenuation correction

PET image fused with CT

Respiratory Motion Artifacts



Attenuation artifacts can dominate true tracer uptake values

PET Signal, Bias, and Noise







True coincidence (T): line integral signal we want but effected by photon counting noise Scattered coincidence (S): bias and noise added to data Random coincidence (R): different type of bias added to data, also noise

Components of measured PET data

 $P = \wp \{aT\} + \wp \{S\} + \wp \{R\}$

Measured Projections attenuated True Signal bias from Scatter

bias from Random events

$$T = \phi'(l,\theta) = \int_{-\infty}^{\infty} A(x(s), y(s)) ds$$

 $\mathcal{O}{x}$, Poisson random process with mean x

If we can estimate S and R as S' and R' (how is beyond scope of this lecture) then:

$$\int_{-\infty}^{\infty} A(x(s), y(s)) ds \simeq \frac{1}{a} \left(P - S' - R' \right)$$

We can solve this with FBP

Signal to Noise Ratio (SNR)

- Signal is the true counts T
- The noise is the total noise in the data P
- We can estimate noise by realizing that photon counting is a Poisson process, so the variance is equal to the mean

$$\sigma(P) = \sqrt{T + S + \alpha R}$$

$$\text{SNR} = \frac{T}{\sigma(P)} \approx \frac{T}{\sqrt{T + S + \alpha R}} = \sqrt{\text{NEC}}$$

 $NEC = \frac{T^2}{T + S + \alpha R} < T$

 α depends on randoms estimation method

NEC is called the 'noise equivalent count' rate, i.e. the useful count rate

The NEC is always less than T

PET Acquisition: 2D vs. 3D Mode

3D mode typically has higher NEC than 2D mode for activity levels of interest



Impact of 3D and 2D mode on NEC rates



Spatial Resolution component of SNR

- Positron Physics
 - Positron Range
 - Photon Non-colinearity
- Detectors
 - Response function

Resolution components add in quadrature

$$R_{system} = \sqrt{R_{pos.phys.}^2 + R_{det}^2 + R_{sampl}^2 + R_{recon}^2}$$

- Ring Geometry
 - Non-uniform LOR sampling
 - Depth-of-interaction
- Reconstruction Filters

Size-Dependent Resolution Losses



Modified NEMA NU-2 IQ Phantom

Recovery coefficient (RC) = measured/true (ideally 100%)



SNM Torso phantom with 1 cm spheres

Increasing smoothing reduces both signal and noise



Clinical examples

Typical PET/CT Scan Protocol



2. Selection of scan region



Scout scan image





Reminder: Data Flow and Processing

CT images are also used for calibration (attenuation correction) of the PET data



• Note that images are not really fused, but are displayed as fused or sideby-side with linked cursors

PET/CT for precise localization



- 68-y-old man, 3 y after partial gastrectomy for adenocarcinoma of stomach
- Referred for 18F-FDG PET/CT for evaluation of mass detected on routine follow-up gastroscopy and equivocal biopsy results
- (A) 18F-FDG PET show increased 18F-FDG uptake in region of stomach (arrow)
- (B) Hybrid PET/CT axial image (top) precisely localizes and defines uptake as physiologic activity at gastric stump (arrowhead). Suspicious mass in anastomotic region (arrow), seen on corresponding hybrid and CT slices (bottom) obtained during same acquisition, shows no uptake of 18F-FDG.
- Findings on PET/CT were interpreted as physiologic 18F-FDG uptake in stomach and nonviable residual mass.
- Patient showed no evidence of disease for follow-up of 7 mo.







- Negative high-resolution contrast-enhanced CT and normal levels of serum tumor markers, was referred for 18F-FDG PET for further assessment of pelvic pain
- (A) Coronal PET images show area of increased 18F-FDG uptake in left pelvic region (arrow), interpreted as equivocal for malignancy, possibly related to inflammatory changes associated with ureteral stent or to physiologic bowel uptake
- (B) Hybrid PET/CT axial image (top) precisely localizes uptake to soft-tissue mass adjacent to left ureter, anterior to left iliac vessels. Mass (arrow) was detected only retrospectively on both diagnostic CT and CT component of hybrid imaging study
- Patient received chemotherapy, resulting in pain relief and decrease in size of pelvic mass on follow-up CT.



PET/CT for precise localization





- A 33-y-old man with Hodgkin's disease in left cervical region was referred for 18F-FDG PET for staging
- · No other sites of disease were reported on CT
- (A) PET images show infradiaphragmatic focus of abnormal 18F-FDG uptake in medial border of liver, consistent with either liver involvement (stage IV disease?) or nodal disease in porta hepatis (stage III disease?)
- (B) Hybrid PET/CT axial image precisely localizes 18F-FDG uptake to adenopathy (abnormally large lymph node) at porta hepatis, only retrospectively detected on corresponding CT image (arrow)
- Patient was treated as having stage III disease and achieved complete response, showing no evidence of disease for follow-up of 12 mo.